Cardiac resynchronization therapy reduced LV end-diastolic and end-systolic volumes, increased ejection fraction, and improved myocardial performance index at 6 months (P < 0.001).
Does cardiac resynchronization therapy improve left ventricular size and function in patients with moderate to severe systolic heart failure and ventricular dyssynchrony?
Cardiac resynchronization therapy induces significant reverse left ventricular remodeling and improves both systolic and diastolic function in patients with moderate-to-severe heart failure.
Absolute Event Rate: 0% vs 0%
Background— Cardiac resynchronization therapy (CRT) has recently emerged as an effective treatment for patients with moderate to severe systolic heart failure and ventricular dyssynchrony. The purpose of the present study was to determine whether improvements in left ventricular (LV) size and function were associated with CRT. Methods and Results— Doppler echocardiograms were obtained at baseline and at 3 and 6 months after therapy in 323 patients enrolled in the Multicenter InSync Randomized Clinical Evaluation (MIRACLE) trial. Of these, 172 patients were randomized to CRT on and 151 patients to CRT off. Measurements were made of LV end-diastolic and end-systolic volumes, ejection fraction, LV mass, severity of mitral regurgitation (MR), peak transmitral velocities during early (E-wave) and late (A-wave) diastolic filling, and the myocardial performance index. At 6 months, CRT was associated with reduced end-diastolic and end-systolic volumes (both P <0.001), reduced LV mass ( P <0.01), increased ejection fraction ( P <0.001), reduced MR ( P <0.001), and improved myocardial performance index ( P <0.001) compared with control. β-Blocker treatment status did not influence the effect of CRT. Improvements with CRT were greater in patients with a nonischemic versus ischemic cause of heart failure. Conclusions— CRT in patients with moderate-to-severe heart failure who were treated with optimal medical therapy is associated with reverse LV remodeling, improved systolic and diastolic function, and decreased MR. LV remodeling likely contributes to the symptomatic benefits of CRT and may herald improved longer-term survival.
Sutton et al. (Mon,) reported a other. Cardiac resynchronization therapy reduced LV end-diastolic and end-systolic volumes, increased ejection fraction, and improved myocardial performance index at 6 months (P < 0.001).